1. Introduction
===============

Colorectal cancer (CRC) is one of the most common cancers of the digestive track and the third leading cause of cancer-related death in the world.^\[[@R1]\]^ Although there have been rapid developments in diagnostic and treatment technologies, 5-year survival rates are not promising for postsurgery of CRC as result of tumor local recurrence or distal metastasis.^\[[@R2],[@R3]\]^

Currently, the classical TNM staging system has been commonly considered the suitable methods to estimate the outcomes in patients with CRC, which focuses on tumor, nodes, distal metastasis. As "gold standard" for guiding therapy,^\[[@R4]\]^ these systems are also limited for predicting the prognosis precisely and guiding the clinical practice appropriately, because many patients with the same stage turned out to be significantly heterogeneous prognosis.^\[[@R5],[@R6]\]^ Therefore, it is vital to seek appropriate prognostic factors for these patients in order to choose patients for systematic treatment.

Recently, the systemic inflammation status is revealed to be associated with the prognosis of solid tumors.^\[[@R7],[@R8]\]^ Some sensitive biomarkers can be obtained before pretreatment, which could be novel and convenient for these patients to design the appropriate therapeutic strategy and assess prognosis. Studies have demonstrated that biomarkers may provide insight into resectability of carcinoma than conventional pathological staging classifications.^\[[@R9],[@R10]\]^ Inflammatory markers contain typical C-reactive protein (CRP) in several cancers, frequently reported neutrophil to lymphocyte ratio (NLR) in various types of cancer, and platelet--lymphocyte ratio (PLR) and so on.^\[[@R11]--[@R13]\]^ The high CRP was regarded as the relationship with poor prognostic factor of cancer,^\[[@R14]\]^ and a promising predictor of recurrence and prognosis in patients with rectal cancer treated by chemoradiotherapy.^\[[@R15]\]^ An elevated NLR has been found to be an indicator of poor prognosis in patients with CRC.^\[[@R16]\]^ As for PLR, owing to the variance in the study design or relatively limited sample sizes, some research showed a decreased survival in patients with elevated PLR,^\[[@R17]--[@R24]\]^ whereas others did not demonstrate the relationship between prognosis and PLR.^\[[@R15],[@R25]--[@R30]\]^ Until now, there was no meta-analysis accessing the prognostic utility of PLR in patients with CRC.

Thus, we perform this meta-analysis to clarify the prognostic value of PLR for predicting CRC. To the best of our knowledge, it is the first meta-analysis investigated the association between elevated pretreatment PLR and clinical outcomes and clinicopathological parameters in CRC.

2. Methods
==========

2.1. Data sources and searches
------------------------------

A systematic literature search was performed in January 2016. Our search strategy included terms for "PLR" \[e.g., "(platelet to lymphocyte ratio," "platelet--lymphocyte ratio," "platelet-to-lymphocyte ratio"\], and "CRC" \[e.g., "colorectal cancer," "colon cancer," "rectal cancer"\]. Using the above search term, PubMed, Embase, Cochrane Library, and Web of Science databases were queried. No language and publication type was restricted.

The institutional review board of the Shengjing Hospital Affiliated with China Medical University approved the study. All procedures were performed in accordance with the Declaration of Helsinki.

2.2. Study selection and data extraction
----------------------------------------

Studies meeting the following criteria were included: the diagnosis of CRC was diagnosed from pathological examination; the PLR was measured with a peripheral blood test before treatment and (or) the present clinical guidelines; association of pretreatment PLR with overall survival (OS), disease-free survival (DFS), or others relevant prognosis was informed; if studies' hazard ratios (HRs) were not directly reported, estimation of the HR could be reconstructed by other data^\[[@R31]\]^; if multiple articles were on the same study population partially overlapping patients, only the most complete and typical study was included. We excluded editorials, comments, abstracts, meetings, or case reports. The selection of studies scanned independently by 2 of the authors (DT and YF), and a third person (QS) was consulted to resolve any disagreements. The relevant information was collected, which contained the following: study information: the first author\'s last name, year of publication, study location, research time, and sample size; patient information: age, stage of disease, treatment method, and follow-up time; cutoff value of NLR, and HR, 95% CI or *P* value of PLR for OS and DFS.

2.3. Assessment of paper quality
--------------------------------

The Newcastle--Ottawa Scale (NOS), which was designed for retrospective and prospective studies, was adopted to assess studies quality included in this research.^\[[@R32]\]^ A high-quality study was defined as the study with ≥6 points on NOS.

2.4. Statistical analysis
-------------------------

We calculated pooled HRs from each study of HRs and their 95% CIs to estimate prognostic role of PLR in CRC patients. If there was significant heterogeneity (*I*^2^ ≥ 50% and *P* \< 0.1), random effects (DerSimonian--Laird method) models were conducted to generate the pooled HRs/ORs. Otherwise, fixed-effects (Mantel--Haenszel method) were performed. Subgroup analysis was applied to explore the possible source of heterogeneity according to the origins of participants (East or West), the therapy of treatment (surgery or nonsurgery), cut-offs (single or multiple), sample size (large or small), and result of study (positive vs negative). ORs were used to estimate the association between PLR and clinicopathological characteristics. Egger linear regression test and Begg funnel plot test were used to evaluate publication bias.^\[[@R33],[@R34]\]^ A trim and fill method was applied to estimate asymmetry in the funnel plot.^\[[@R35]\]^ All statistical analyses including graphical presentations were performed with STATA version 12.0 (StataCorp, CollegeStation, TX, USA). *P* \< 0.05 was considered statistically significant.

3. Results
==========

As shown in Fig. [1](#F1){ref-type="fig"}, we found that the initial search algorithm retrieved a total of 256 studies. After excluding 233 irrelevant or duplicate articles by screening the title and title and abstract, the left 23 full-text articles were reviewed. Of them, another 8 studies had to be excluded, as they were conference abstracts (n = 3), reports without associating PLR with survival parameters, such as OS or DFS (n = 2), or articles without sufficient data (n = 3). Finally, our meta-analysis included 15 studies with a total number of 3991 patients to assess the value of PLR as prognostic biomarkers in CRC. The basic characteristics of the 15 studies are summarized in Table [1](#T1){ref-type="table"}. There were 14 studies that reported the association between the PLR and OS. Six studies evaluated the NLR for outcomes of patients. Of the 15 eligible articles, 4 studies were from China, 2 cohorts from the UK, 1 cohort from the Austria, 3 from the Korea, 3 from the Japan, 1 from Hungary, and 1 from Canada. Six groups in the original multivariate analysis directly provided HR, and there were 4 HRs coming from univariate analysis and 5 HRs deduced from survival curves. For the risk of OS, PLR was related with poor survival in 7 studies,^\[[@R17]--[@R24]\]^ and the rest of studies did not show the relationship between the PLA and decreased survival.^\[[@R15],[@R25]--[@R30]\]^

![Flow chat of literature search and selection.](medi-95-e3837-g001){#F1}

###### 

Main characteristics of all the studies included in the meta-analysis.

![](medi-95-e3837-g002)

4. Meta-analysis
================

4.1. PLR and OS
---------------

There was significant heterogeneity between studies for categorized PLR (*I*^2^ = 55.80%; *P* = 0.006) in the 14 studies evaluating OS, so the random-effect model was performed to calculate the pooled HR, and its 95% CI. The pooled HR of 1.53 (95% CI, 1.24--1.89) indicated that patients with elevated PLR have shorter OS (Fig. [2](#F2){ref-type="fig"}A).

![(A) Meta-analysis of the association between elevated PLR and OS in patients with CRC, and (B) Forest plot of studies evaluating the association between PLR and DFS in CRC.](medi-95-e3837-g003){#F2}

4.2. PLR and DFS
----------------

We observed a significant subtle positive association between PLR and the DFS of patients (synthesized HR, 1.68; 95% CI, 1.07--2.62; *P* = 0.023) after pooling the data with heterogeneity (*I*^2^ = 69.80%, *P* = 0.005), indicating that higher PLR values were likely to predict poor DFS (Fig. [2](#F2){ref-type="fig"}B).

4.3. Subgroup analysis and meta-regression
------------------------------------------

It is the heterogeneity that was significantly apparent in both pooled HR of OS (*I*^2^ = 55.8%, *P* = 0.006) and DFS (*I*^2^ = 69.8%, *P* = 0.005), so we tried to identify the source of heterogeneity in the present study. The subgroup analysis was stratified to evaluate HR of OS and by region (eastern vs western), major therapy (surgery vs non-surgery), respective cut-off value (single vs multiple), sample size (large vs small), and the result of HR (positive vs negative). In multivariate analysis, meta-regression was used to explain the source of the heterogeneity, and the rest subgroup of results showed that region of publication (*P* = 0.687), therapeutic schedule (*P* = 0.853), respective cut-off value (*P* = 0.117), and sample size (*P* = 0.702) did not obviously contribute to the source of heterogeneity (Table [2](#T2){ref-type="table"}). But the result of studies (positive vs negative) might partly explain the source of heterogeneity (*P* = 0.009). The results are the same with univariate analysis. Given the small number of studies for DFS, the meta-regression analysis was not conducted.

###### 

Summary of the subgroup analysis and the meta-regression results.
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4.4. Sensitivity analyses
-------------------------

We removed 1 study each time to check the influence of the individual data set to the pooled HRs of OS. The combined HR and its 95% CIs were not obviously affected. The result confirmed the robustness of the outcome of this study (Fig. [3](#F3){ref-type="fig"}A). However, the combined HR of DFS did not show robustness of the outcome of this study after deleting 1 study each time (Fig. [3](#F3){ref-type="fig"}B).

![(A) Sensitivity analyses for confirming robustness of OS by removing 1 study each time, while (B) the corresponding pooled HRs of DFS were materially changed by deleting each time.](medi-95-e3837-g005){#F3}

4.5. Publication bias
---------------------

There was publication bias in OS (*P* = 0.013) and DFS (*P* = 0.025) among these included studies as inferred through the visual inspection of the Begg funnel plot or Egger plot. Therefore, we needed to use a trim and fill method to estimate the asymmetry in the funnel plot. With filled unpublished studies, the recalculated pooled HRs of OS did not significantly alter by filling 5 unpublished studies (HR, 1.39; 95% CI, 1.14--1.69; *P* = 0.008; Fig. [4](#F4){ref-type="fig"}A). However, the pooled HRs did not show the correlation between PLR and DFS (HR, 1.40; 95% CI, 0.95--2.01; *P* \< 0.001; Fig. [4](#F4){ref-type="fig"}B).

![Funnel plot adjusted using a trim and fill method for (A) OS, and (B) for DFS. Diamonds: Included studies; diamonds in squares: Presumed missing studies.](medi-95-e3837-g006){#F4}

4.6. PLR and tumor clinicopathologic parameters
-----------------------------------------------

A total of 7 studies reported that the correlation between the PLR and tumor differentiation, and the combined data showed that high PLR was related with poor tumor differentiation (OR, 2.12; 95% CI, 1.45--3.08; *P* \< 0.001, Fig. [5](#F5){ref-type="fig"}A) with no heterogeneity. There were 6 retrieved cohorts about information on PLR and clinical stage, but the pooled estimates did not display that elevated pretreatment PLR tended to be linked with advancing clinical stage (OR, 1.29; 95% CI, 0.86--1.96; *P* = 0.220; Fig. [5](#F5){ref-type="fig"}B). The combined estimates (OR, 1.69; 95% CI, 1.20--2.39; *P* = 0.003; Fig. [5](#F5){ref-type="fig"}C) indicated that patients with higher PLR showed propensity toward depth of infiltration with no obvious heterogeneity. The synthesized data from 2 research showed that elevated PLR was associated with recurrence of CRC (HR, 2.71; 95% CI, 1.31--5.60; *P* = 0.005; Fig. [5](#F5){ref-type="fig"}D).

![Forest plots showing the odds ratio (OR) and the corresponding 95% confidence intervals (CIs), describing the association between elevated PLR and clinicopathological parameters. (A) Degree of tumor differentiation (poor vs well or moderate); (B) clinical stage (I+II vs III+IV); (C) depth of infiltration (T1+T2 vs T3+T4); (D) tumor of recurrence (yes vs no).](medi-95-e3837-g007){#F5}

5. Discussion
=============

Our meta-analysis, including 15 individual studies of 4001 patients, demonstrated that elevated PLR was associated with poor OS through a random-effects model, but not DFS, in patients with CRC. In addition, subgroup analyses suggested that a high PLR was an effective prognostic factor for poor survival patients who underwent resection, but we did not find the correlation between the elevated PLR and prognosis of patients who received nonsurgery. We also found that elevated PLR was related with poor tumor differentiation, T grade development, and recurrence. This finding suggested a potential role for PLR as a predictor of survival, particularly in terms of postresection follow-up.

The systemic inflammatory response plays an important role in the progression of numerous cancers through genetic mutations, genomic instability, and epigenetic modifications, tumor metastasis, and cancer cell proliferation during different stages of tumor development.^\[[@R8],[@R36]\]^ Recent research have shown platelet secreting several angiogenic and tumor growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, which might influence tumor progression, and also release microparticles that help tumor cells escape from the elimination of natural killer.^\[[@R37],[@R38]\]^ On the contrary, lymphocytes are basic components of the adaptive and innate immune system and the cellular basis of immunosurveillance and immunoediting, and CD8^+^ and CD4^+^ T-lymphocyte interaction among each other could be proven to induce tumor cell apoptosis in antitumor reaction of the immune system, which has been demonstrated to increase the survival of patients for the efficacy of chemotherapy in CRC patients.^\[[@R39]--[@R41]\]^ Taken together, the relative ratio of elevated platelets and decreased lymphocytes predicts the prognosis of patients with CRC. Current opinion on the prognostic role of the PLR in CRC is inconsistent and inconclusive.

Our results of meta-analysis indicated that pretreatment PLR was predictive of OS. As routinely available and less expensive in many hospitals, PLR tests may be widely applied in prognosis of patients with CRC, especially for curative resection. However, we did not find that elevated PLR was related with the combined DFS after adjusting for heterogeneity and publication bias. This result of study may come from limiting studies.

There are still some limitations in our meta-analysis. First, the majority of the enrolled studies in our meta-analysis were retrospective, which led to be more prone to some biases. Second, heterogeneity was observed among the included studies for OS and DFS. The results of our meta-regression suggested that the result of HR is a vital source of heterogeneity among the included studies. In addition, many other possible factors could cause the heterogeneity, such as histology type, TNM stage differences, study region, treatment method, PLR cutting value, and estimate method of HR. After sensitivity analyses, prognostic value was not weakened. Third, there were 5 HRs of studies that recalculated the HR on the basis of the method reported by Parmar et al,^\[[@R31]\]^ which also contributed to the heterogeneity of pooled HR. Moreover, there is another inevitable problem that is publication bias. Studies are easier to be published with positive results. Through trim and fill analysis, the outcome of this study with OS upholds the prognostic role of PLR in CRC patients. However, the conjoined HR of DFS was undermined after sensitivity analyses and "trim and fill" analysis. Additional large cohorts of prospective studies are needed to correct for heterogeneity and publication bias.

In conclusion, the pretreatment PLR is a useful factor to predict the OS in CRC and connected with clinicopathological parameters, not for DFS. These ratios may thus contribute to inform more personalized treatment decisions and predict treatment outcomes.

We acknowledge all clinical researchers of the selected studies and patients related to these studies.

Abbreviations: PLR = platelet--lymphocyte ratio, CI = confidence interval, CRC = colorectal cancer, OS = overall survival, DFS = disease-free survival, HR = hazard ratio, TNM = tumor--node--metastasis, CRP = C reactive protein, NLR = neutrophil to lymphocyte ratio, OR = odds ratio.
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